Skip to main content
SpringerLink
Log in

Reassessing the Relevance of Pharmacoeconomic Analyses in Formulary Decisions

  • Current Opinion
  • Pharmacoeconomic Analyses in Formulary Decisions
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lipsey RJ. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions. Pharmacoeconomics 1992; 1 (4): 265–81

    Article  Google Scholar 

  2. Johnson JA, Bootman JL. Pharmacoeconomic analysis in formulary decision: an international perspective. Am J Hosp Pharm 1994; 51: 2593–8

    PubMed  CAS  Google Scholar 

  3. Genduso LA, Kotsanos JG. Review of health economic guidelines in the form of regulations, principles, policies and positions. Drug Inf J 1996; 30: 1003–16

    Article  Google Scholar 

  4. Mitchell AS. Current experience in Australia. Drug Inf J 1996; 30: 495–502

    Article  Google Scholar 

  5. Torrance G. Current experience with guidelines for economic evaluation in Canada. Drug Inf J 1996; 30: 507–11

    Article  Google Scholar 

  6. Menon D, Schubert F, Torrance GW. Canada’s new guidelines for the economic evaluation of pharmaceuticals. Med Care 1996; 34 Suppl.: DS77–86

    Google Scholar 

  7. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: CCOHTA, 1997

  8. Golde MR, Seigel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996

    Google Scholar 

  9. Drummond MF. Introduction: the rationale for guidelines. Drug Inf J 1996; 30: 491–3

    Article  Google Scholar 

  10. Mason J. The generalisability of pharmacoeconomic studies. Pharmacoeconomics 1997; 11 (6): 503–14

    Article  PubMed  CAS  Google Scholar 

  11. Cooke J. The practical impact of pharmacoeconomics on institutional managers. Pharmacoeconomics 1994; 6 (4): 289–97

    PubMed  CAS  Google Scholar 

  12. Nash DB, Catalano ML, Wordell CJ. The formulary decisionmaking process in a US academic medical centre. Pharmacoeconomics 1993; 3 (1): 22–35

    Article  PubMed  CAS  Google Scholar 

  13. Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ 1995; 4: 355–71

    Article  PubMed  CAS  Google Scholar 

  14. O’Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: issues in design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32: 150–63

    Article  PubMed  Google Scholar 

  15. Armstrong EP, Langley PC. Disease management programs. Am J Health Syst Pharm 1996; 53: 53–8

    PubMed  CAS  Google Scholar 

  16. Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997

    Google Scholar 

  17. O’Brien B. Economic evaluation of pharmaceuticals: Frankenstein’s monster or vampire of trials? Med Care 1996; 34 (12 Suppl.): DS99–108

    Google Scholar 

  18. Guyatt GH, Sackett DL, Sinclair JC, Evidenced-Based Medicine Working Group, et al. Users’ guides to medical literature. IX: a method for grading health care recommendations. JAMA 1995; 274: 1800–4

    Article  PubMed  CAS  Google Scholar 

  19. Hadorn DC, Baker D, Hodges JS, et al. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 1996; 49: 749–54

    Article  PubMed  CAS  Google Scholar 

  20. MacPherson P. The FDA just says yes. Hosp Health Netw 1996; 70 (10): 34–8

    PubMed  CAS  Google Scholar 

  21. Hochla PKO, Tuason VB. Pharmacy and Therapeutics Committee: cost containment considerations. Arch Intern Med 1992; 152: 1773-5

    Google Scholar 

  22. Soumerai SB, Ross-Degnan D, Avorn J, et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 1991; 325: 1072–7

    Article  PubMed  CAS  Google Scholar 

  23. Schroeder SA, Cantor JC. On squeezing balloons: cost control fails again. N Engl J Med 1991; 325: 1099–100

    Article  PubMed  CAS  Google Scholar 

  24. Soumerai SB, Ross-Degnan D, Gortmaker S, et al. Withdrawing payment for nonscientific drug therapy: intended and unexpected effects of a large-scale natural experiment. JAMA 1990; 263: 831–9

    Article  PubMed  CAS  Google Scholar 

  25. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994; 331: 650–5

    Article  PubMed  CAS  Google Scholar 

  26. Horn SD, Sharkey PD, Tracy DM, et al. Intended and unintended consequences of HMO cost-containment strategies: results from the Managed Care Outcomes Project. Am J Manage Care 1996; 2: 253–64

    Google Scholar 

  27. Maynard A. Developing the health care market. Econ J 1991; 101: 1277–86

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

    Jeffrey A. Johnson & Erwin Friesen

  2. Institute of Pharmaco-Economics, #710, 10665 Jasper Avenue, Edmonton, Alberta, T5J 3S9, Canada

    Jeffrey A. Johnson

  3. Pharmacoeconomics, Regional Pharmacy Services, Capital Health Authority, Edmonton, Alberta, Canada

    Erwin Friesen

Authors
  1. Jeffrey A. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erwin Friesen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey A. Johnson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnson, J.A., Friesen, E. Reassessing the Relevance of Pharmacoeconomic Analyses in Formulary Decisions. Pharmacoeconomics 13, 479–485 (1998). https://doi.org/10.2165/00019053-199813050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199813050-00001

Keywords

Search

Navigation